BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21990165)

  • 1. Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.
    Vallée MP; Francy TC; Judkins MK; Babikyan D; Lesueur F; Gammon A; Goldgar DE; Couch FJ; Tavtigian SV
    Hum Mutat; 2012 Jan; 33(1):22-8. PubMed ID: 21990165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants.
    Vallée MP; Di Sera TL; Nix DA; Paquette AM; Parsons MT; Bell R; Hoffman A; Hogervorst FB; Goldgar DE; Spurdle AB; Tavtigian SV
    Hum Mutat; 2016 Jul; 37(7):627-39. PubMed ID: 26913838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
    Tavtigian SV; Deffenbaugh AM; Yin L; Judkins T; Scholl T; Samollow PB; de Silva D; Zharkikh A; Thomas A
    J Med Genet; 2006 Apr; 43(4):295-305. PubMed ID: 16014699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically Significant Unclassified Variants in
    Yoon KA; Park B; Lee BI; Yang MJ; Kong SY; Lee ES
    Cancer Res Treat; 2017 Jul; 49(3):627-634. PubMed ID: 27658390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
    Gómez García EB; Oosterwijk JC; Timmermans M; van Asperen CJ; Hogervorst FB; Hoogerbrugge N; Oldenburg R; Verhoef S; Dommering CJ; Ausems MG; van Os TA; van der Hout AH; Ligtenberg M; van den Ouweland A; van der Luijt RB; Wijnen JT; Gille JJ; Lindsey PJ; Devilee P; Blok MJ; Vreeswijk MP
    Breast Cancer Res; 2009; 11(1):R8. PubMed ID: 19200354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
    Lindor NM; Guidugli L; Wang X; Vallée MP; Monteiro AN; Tavtigian S; Goldgar DE; Couch FJ
    Hum Mutat; 2012 Jan; 33(1):8-21. PubMed ID: 21990134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
    Cline MS; Liao RG; Parsons MT; Paten B; Alquaddoomi F; Antoniou A; Baxter S; Brody L; Cook-Deegan R; Coffin A; Couch FJ; Craft B; Currie R; Dlott CC; Dolman L; den Dunnen JT; Dyke SOM; Domchek SM; Easton D; Fischmann Z; Foulkes WD; Garber J; Goldgar D; Goldman MJ; Goodhand P; Harrison S; Haussler D; Kato K; Knoppers B; Markello C; Nussbaum R; Offit K; Plon SE; Rashbass J; Rehm HL; Robson M; Rubinstein WS; Stoppa-Lyonnet D; Tavtigian S; Thorogood A; Zhang C; Zimmermann M; ; Burn J; Chanock S; Rätsch G; Spurdle AB
    PLoS Genet; 2018 Dec; 14(12):e1007752. PubMed ID: 30586411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
    Spurdle AB; Healey S; Devereau A; Hogervorst FB; Monteiro AN; Nathanson KL; Radice P; Stoppa-Lyonnet D; Tavtigian S; Wappenschmidt B; Couch FJ; Goldgar DE;
    Hum Mutat; 2012 Jan; 33(1):2-7. PubMed ID: 21990146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unclassified variants in BRCA genes: guidelines for interpretation.
    Radice P; De Summa S; Caleca L; Tommasi S
    Ann Oncol; 2011 Jan; 22 Suppl 1():i18-23. PubMed ID: 21285146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
    Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
    J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases.
    Caputo S; Benboudjema L; Sinilnikova O; Rouleau E; Béroud C; Lidereau R;
    Nucleic Acids Res; 2012 Jan; 40(Database issue):D992-1002. PubMed ID: 22144684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid screening test of most frequent BRCA1/BRCA2 pathogenic variants in the NGS era.
    Zidekova D; Waczulikova I; Dolesova L; Vavrova L; Hamidova O; Lohajova Behulova R; Konecny M
    Neoplasma; 2018; 65(2):309-315. PubMed ID: 29534594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots".
    Dines JN; Shirts BH; Slavin TP; Walsh T; King MC; Fowler DM; Pritchard CC
    Genet Med; 2020 May; 22(5):825-830. PubMed ID: 31911673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing.
    Brandão RD; van Roozendaal K; Tserpelis D; Gómez García E; Blok MJ
    Breast Cancer Res Treat; 2011 Oct; 129(3):971-82. PubMed ID: 21638052
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
    Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
    [No Abstract]   [Full Text] [Related]  

  • 19. The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding.
    Millevoi S; Bernat S; Telly D; Fouque F; Gladieff L; Favre G; Vagner S; Toulas C
    Breast Cancer Res Treat; 2010 Apr; 120(2):391-9. PubMed ID: 19404736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization, homology modeling and docking studies of the R2787H missense variation in BRCA2 gene: Association with breast cancer.
    Riahi A; Messaoudi A; Mrad R; Fourati A; Chabouni-Bouhamed H; Kharrat M
    J Theor Biol; 2016 Aug; 403():188-196. PubMed ID: 27211102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.